Anti-a-MMP9 [4A3]
Invented by Ayham Alnabulsi from Vertebrate Antibodies Limited
Invented at Vertebrate Antibodies Limited
- Datasheet
- References (5)
- Inventor Info
Info
![Image thumbnail for Anti-a-MMP9 [4A3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/dde2087f-0436-451b-b81c-992a63b46826.jpg)
![Image thumbnail for Anti-a-MMP9 [4A3]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/e34a0829-dfc0-4d86-9249-5643d0b93b63.jpg)
| Catalogue Number | 151622 |
| Applications | ELISA IHC WB |
| Antigen/Gene or Protein Targets | Activated MMP9 (matrix metalloproteinase 9) |
| Reactivity | Human and Rat |
| Relevance | Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis |
| Host | Mouse |
| Immunogen | Ovalbumin-conjugated synthetic peptide; acetylated-FQTFEGDLK |
| Positive Control | IHC: Formaldehyde-fixed, wax-embedded oesophegal adenocarcinomaWestern Blot Activated recombinant MMP-9, 400ng per lane |
| Subclass | IgG1 kappa |
| Myeloma Used | P3X63Ag8.653 |
| Recommended Growing Conditions | Dulbecco’s media containing L-Glutamine and 20% Fetal Bovine serum (DH20) . |
| Strain | Balb/c |
| Notes | Western Blot: not reactive with proenzyme of MMP-9, nor proenzyme or activated forms of MMP-2 |
| Research Area | Adhesion, Cancer, Cardiovascular, Cell Signaling & Signal Transduction, Protein Degradation |
References: 5 entries
Cirella et al. 2016. Thesis
WB
Goktolga et al. 2015. Exp Ther Med. 9(5):1813-1818. PMID: 26136898.
IHC
Effect of the non-specific matrix metalloproteinase inhibitor Doxycycline on endometriotic implants in an experimental rat model.
Europe PMC ID: 26136898
Duncan et al. 1998. Eur J Biochem. 258(1):37-43. PMID: 9851689.
Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form.
Europe PMC ID: 9851689
Add a reference
References: 5 entries
Cirella et al. 2016. Thesis
WB
Goktolga et al. 2015. Exp Ther Med. 9(5):1813-1818. PMID: 26136898.
IHC
Effect of the non-specific matrix metalloproteinase inhibitor Doxycycline on endometriotic implants in an experimental rat model.
Duncan et al. 1998. Eur J Biochem. 258(1):37-43. PMID: 9851689.
Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form.
Add a reference
